Insulinoma: Difference between revisions

	Insulinoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Insulinoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
X-ray
Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Insulinoma On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Insulinoma All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Insulinoma
CDC on Insulinoma
Insulinoma in the news
Blogs on Insulinoma
Directions to Hospitals Treating Insulinoma
Risk calculators and risk factors for Insulinoma

	Insulinoma;
	Histopathology of pancreatic endocrine tumor (insulinoma).
ICD-10	C25.4, D13.7
ICD-9	157.4, 211.7
ICD-O:	8151
DiseasesDB	6830
MeSH	D007340

VisualWikitext

Revision as of 15:08, 17 January 2012

For patient information click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Historical Perspective

Pathophysiology

Epidemiology & Demographics

Risk Factors

Screening

Causes

Differentiating Insulinoma

Complications & Prognosis

Diagnosis

Treatment

Prognosis

Most patients with benign insulinomas can be cured with surgery. Persistent or recurrent hypoglycemia after surgery tends to occur in patients with multiple tumours. About two percent of patients develop diabetes mellitus after their surgery.

History

Hypoglycemia was first recognized in the 19th century. In the 1920’s, after the discovery of insulin and its use in the treatment of diabetics, hyperinsulinism was suspected to be a cause of hypoglycemia in non-diabetics. The first report of a surgical cure of hypoglycemia by removing an islet cell tumour was in 1929.

External links

www.endotext.org article

Template:Tumor morphology de:Insulinom he:אינסולינומה nl:Insulinoom fi:Insulinooma

Template:WikiDoc Sources

@@ Line 41: / Line 41: @@
 ==Treatment==
 [[Insulinoma medical therapy|Medical therapy]] | [[Insulinoma surgery|Surgical options]] | [[Insulinoma primary prevention|Primary prevention]]  | [[Insulinoma secondary prevention|Secondary prevention]] | [[Insulinoma cost-effectiveness of therapy|Financial costs]] | [[Insulinoma future or investigational therapies|Future therapies]]
-==Treatment==
-Medications such as [[diazoxide]] and [[somatostatin]] can be used to block the release of insulin for patients who are not surgical candidates or who otherwise have inoperable tumours.<br/>
-[[Streptozotocin]] is used in [[islet cell carcinoma]]s which produce excessive insulin.  Combination [[chemotherapy]] is used: either [[doxorubicin]] + streptozotocin, or [[fluorouracil]] + streptotozocin in patients where doxorubicin is contraindicated.[http://www.cancer.gov/cancertopics/pdq/treatment/isletcell/HealthProfessional/page6] <br>
-In metastasizing tumours with intrahepatic growth, [[hepatic artery|hepatic arterial]] occlusion or [[embolization]] can be used. [http://www.nci.nih.gov/cancertopics/pdq/treatment/isletcell/Patient/page5]
 ==Prognosis==